drugset / Trial / NCT05984927
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).
Timeline
- Start
- 2023-09-08
- Primary completion
- 2026-01
- Completion
- 2030-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | metopimazine | Gene therapy (AAV / viral vector) | 1e+09 vg | Other |
| Subject | metopimazine | Gene therapy (AAV / viral vector) | 3e+09 vg | Other |
| Subject | metopimazine | Gene therapy (AAV / viral vector) | 8e+09 vg | Other |